Overview

68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging

Status:
Recruiting
Trial end date:
2020-12-17
Target enrollment:
Participant gender:
Summary
Patients with primary intermediate risk prostate cancer for whom radical prostatectomy is indicated, will be invited to participate to the present study. Positron Emission Tomography coupled with scanner (PET-CT) using a radiotracer : 68Ga-RM2 and Positron Emission Tomography coupled with scanner (PET-CT) using another radiotracer : 68Ga-PSMA-617, will be scheduled.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Bordeaux
Treatments:
Gallium 68 PSMA-11